DEF: Ensysce Seeks Shareholder Approval for Equity Issuance, Incentive Plan

Ensysce Biosciences, Inc. calls for its Annual Meeting on December 23, 2025, to seek stockholder approval for a significant equity issuance to an institutional investor, an increase in its incentive plan share reserve, and director elections.

Summary

• Stockholders are asked to approve, for Nasdaq compliance, the full issuance of common stock and exercise of warrants to an institutional investor, which could result in the investor holding 43% of common stock post-transaction.
• A proposal to amend the 2021 Omnibus Incentive Plan will increase the aggregate number of shares available for issuance from 121,457 to 721,457 shares.
• Two Class I directors, William Chang and Lee Rauch, are nominated for re-election to hold office until the 2028 Annual Meeting.
• The appointment of Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, is up for ratification.
• Stockholders will also consider and vote upon the adjournment of the Annual Meeting, if necessary, to solicit additional proxies.
• The Board of Directors recommends that stockholders vote FOR all proposals.

Sentiment

Score: 3

Explanation: The company is in a difficult financial position, requiring significant dilution to raise capital and maintain operations. While the capital raise is a positive for immediate survival, the terms and historical performance are concerning.

Positives

• The company secured approximately $3.6 million in estimated net proceeds from recent offerings, which will provide necessary working capital for continued development of its TAAP and MPAR programs and lead program PF614.
• The proposed increase in the share reserve for the 2021 Omnibus Incentive Plan is intended to help attract, retain, and motivate talented employees, consultants, and non-employee directors, aligning their interests with stockholders.
• The company is actively addressing Nasdaq listing rule compliance by seeking stockholder approval for the equity issuance.

Negatives

• The equity issuance and warrant exercise could lead to significant shareholder dilution, with the institutional investor potentially holding 2,640,000 shares, representing 75% of outstanding common stock on a pre-transaction basis and 43% on a post-transaction basis.
• The conversion and exercise prices of the warrants are subject to adjustment, which could result in even greater dilutive effects for current stockholders.
• Failure to approve Proposal 1 would obligate the company to call stockholder meetings every 45 days until approval is obtained or the warrants are no longer outstanding, incurring additional administrative burden and costs.
• The company's financial condition, results of operations, cash flow, and liquidity require additional capital for ongoing operational needs and to meet listing requirements, indicating financial strain.
• The company reported consistent net losses: ($7,987,225) in 2024, ($10,626,011) in 2023, and ($25,085,496) in 2022.
• Total Shareholder Return (TSR) has been significantly negative, with an initial $100 investment yielding only $0.01 in 2024, $0.09 in 2023, and $0.80 in 2022.

Risks

• Significant shareholder dilution from the issuance of common stock and exercise of warrants to the institutional investor.
• Potential for the institutional investor to significantly influence future company decisions due to their large ownership stake (up to 43% post-transaction).
• Risk of further dilutive effects if the conversion and exercise prices are adjusted lower.
• Risk of non-compliance with Nasdaq rules if Proposal 1 is not approved, leading to continuous stockholder meetings and potential delisting concerns.
• The company's current financial condition and market volatility make it difficult to obtain necessary financing from other sources.
• The increased number of issued shares could have an incidental anti-takeover effect, potentially discouraging or making more difficult certain mergers, tender offers, proxy contests, or other change of control transactions.
• The company's ability to attract and retain key talent is dependent on equity awards, and an insufficient share reserve could hinder this.

Future Outlook

The company intends to use the estimated net proceeds of $3.6 million from the recent offerings for general corporate purposes, including the continued development of its TAAP and MPAR programs and for working capital. The Board believes that increasing the share reserve under the Omnibus Incentive Plan is essential for business growth and to motivate high levels of performance among employees and directors.

Management Comments

• "The Board believes that the approval of the Plan Amendment to increase the share reserve under the Plan is essential to build our business."
• "The Board believes that equity awards in meaningful amounts motivate high levels of performance, align the interests of our employees and stockholders by giving employees the perspective of an owner with an equity stake in the Company, and provide an effective means of recognizing employee contributions to the success of the Company."
• "Our current financial condition, results of operations, cash flow and liquidity, which require us to raise additional capital for ongoing operational needs and to meet listing requirements."
• "We are not aware of an ability for us to obtain the financing needed for our interim cash needs from other sources at this time."

Industry Context

The company operates in the biopharmaceutical industry, focusing on drug discovery and development, particularly for pain therapies. The need for significant capital to fund clinical trials and ongoing R&D is characteristic of this sector, where high costs and long development timelines are common. The reliance on equity financing and incentive plans to attract and retain specialized talent is also a standard practice in competitive biotech markets. The company's consistent net losses and negative Total Shareholder Return reflect the inherent high-risk, high-reward nature of drug development, where substantial investment is typically required before potential commercialization and profitability.

Comparison to Industry Standards

• The necessity for capital raises to fund clinical trials is a standard operational aspect for pre-revenue biopharmaceutical companies, aligning with industry norms where research and development is highly capital-intensive.
• The proposed increase in the equity incentive plan to 20% of outstanding shares is a common strategy in the biotech industry to attract and retain key scientific and executive talent, often competing with larger pharmaceutical companies or well-funded startups.
• The significant shareholder dilution (up to 43% post-transaction for a single investor) is a notable concern, potentially higher than typical for non-control-seeking institutional investments, and could be indicative of distressed financing terms or a strategic investment where significant influence is granted.
• The company's sustained negative net income and poor Total Shareholder Return are common for early-stage biotech companies that have not yet brought products to market, but continued performance at these levels warrants careful monitoring against peers in similar development stages and could signal underlying operational challenges.

Management Changes

Corporate Governance

Related Party Transactions

• The company owns 79.2% of EBIR, a clinical stage pharmaceutical company. Dr. Lynn Kirkpatrick, the company's CEO and a director, owns 9.9% of EBIR and also serves as its CEO.
• Bob Gower, the company's Chairman, purchased convertible notes with an aggregate principal amount of $216,000 for a purchase price of $200,000 and warrants exercisable for 29,547 shares of common stock in an offering that closed in October and November 2023.

Stakeholder Impact

• Shareholders face significant dilution from the equity issuance and warrant exercise, which will reduce their percentage ownership and voting power. The market price of common stock could also decline. However, the capital raise is critical for the company's continued operations and clinical development, which could offer long-term benefits if successful.
• Employees, consultants, and directors will benefit from the proposed increase in the Omnibus Incentive Plan share reserve, which aims to attract, retain, and motivate talent through equity awards. Executive officers received a 5% cost of living increase effective March 1, 2025.
• Creditors may see improved liquidity and the company's ability to meet its obligations due to the additional working capital from the capital raise.
• Patients and the public could potentially benefit from the continued development of TAAP and MPAR programs, which are focused on novel pain therapies.

Next Steps

• Hold the Annual Meeting of Stockholders on December 23, 2025, to vote on the proposals.
• Publish final voting results in a Current Report on Form 8-K within four business days after the Annual Meeting.
• Continue development of TAAP and MPAR programs and PF614 and pipeline programs PF614-MPAR using net proceeds.
• Promptly file a resale registration statement for securities issued in the Private Placement.
• If Proposal 1 is not approved, the company will be obligated to call stockholder meetings every 45 days until approval is obtained or warrants are no longer outstanding.
• Implement an annual increase in shares available under the Omnibus Incentive Plan on January 1, 2026, and each anniversary thereafter.

Key Dates

Recommendation

The company is in a precarious financial state, evidenced by consistent and substantial net losses, severely negative Total Shareholder Return, and an explicit statement of needing to raise capital for ongoing operational needs and to meet listing requirements. The proposed capital raise, while necessary for survival, comes at a significant cost of dilution (up to 43% for a single investor post-transaction), which is highly detrimental to existing shareholders. The inability to secure financing from other sources at this time further underscores the challenging position. While the capital will fund critical clinical trials, the high dilution, poor historical performance, and the company's stated financial fragility suggest a high-risk investment with significant downside for current shareholders.

Keywords

Ensysce Biosciences, SEC filing, DEF 14A, proxy statement, equity issuance, warrants, stock options, incentive plan, shareholder approval, Nasdaq compliance, dilution, corporate governance, director election, auditor ratification, clinical trials, TAAP, MPAR, PF614, biotechnology, pharmaceutical, drug development, executive compensation